Proteome studies of bacterial antibiotic resistance mechanisms

Journal of Proteomics

Volumn 97, Issue , 2014, Pages 88-99

  Vranakis, Iosif ^a   Goniotakis, Ioannis ^b   Psaroulaki, Anna ^a,b   Sandalakis, Vassilios ^a   Tselentis, Yannis ^a   Gevaert, Kris ^c,d   Tsiotis, Georgios ^b  

^a Regional Laboratory of Public Health   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d GHENT UNIVERSITY   (Belgium)

Author keywords

Antibiotic resistance; COFRADIC; MS driven proteomics; Quantitative proteomics

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; LIPOPEPTIDE; MACROLIDE; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN SYNTHESIS INHIBITOR; PROTEOME; QUINOLONE DERIVATIVE; RIFAMPICIN; TETRACYCLINE DERIVATIVE; AMINOGLYCOSIDE; BETA LACTAM DERIVATIVE; GLYCOPEPTIDE; POLYPEPTIDE;

ANTIBIOTIC RESISTANCE; BACTERIAL CELL WALL; BACTERIAL GENOME; CELL MEMBRANE; DNA METABOLISM; DNA SYNTHESIS INHIBITION; DRUG TREATMENT FAILURE; GENE EXPRESSION; GENE SEQUENCE; MICROBIAL GENE; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RNA SYNTHESIS; CELL WALL; DNA SYNTHESIS; HUMAN; PROTEIN ANALYSIS;

BACTERIA (MICROORGANISMS);

ANTIBIOTIC RESISTANCE; COFRADIC; MS-DRIVEN PROTEOMICS; QUANTITATIVE PROTEOMICS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; HUMANS; PROTEOME; PROTEOMICS;

EID: 84892900733     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.10.027     Document Type: Review

References (95)

1. Kaplan W., Laing R. Priority medicines for Europe and the world 2004, World Health Organization: Department of Essential Drugs and Medicines Policy.
2. (WHO) WHO Antimicrobial resistance 2002, [Fact sheet No 194].
3. Levy S.B., Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 2004, 10:S122-S129.
4. Lewis D.A., Lukehart S.A. Antimicrobial resistance in Neisseria gonorrhoeae and Treponema pallidum: evolution, therapeutic challenges and the need to strengthen global surveillance. Sex Transm Infect 2011, 87(Suppl. 2):ii39-ii43.
5. Hancock E.W. Mechanisms of action of newer antibiotics for Gram-positive pathogens. Lancet Infect Dis 2005, 5:209-218.
6. Norrby S.R., Nord C.E., Finch R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect Dis 2005, 5:115-119.
7. Riley M., Abe T., Arnaud M.B., Berlyn M.K., Blattner F.R., Chaudhuri R.R., et al. Escherichia coli K-12: a cooperatively developed annotation snapshot-2005. Nucleic Acids Res 2006, 34:1-9.
8. McDermott P.F., Walker R.D., White D.G. Antimicrobials: modes of action and mechanisms of resistance. Int J Toxicol 2003, 22:135-143.
9. Martínez J.L., Rojo F. Metabolic regulation of antibiotic resistance. FEMS Microbiol Rev 2011, 35:768-789.
10. Sandalakis V., Psaroulaki A., De Bock P.J., Christidou A., Gevaert K., Tsiotis G., et al. Investigation of rifampicin resistance mechanisms in Brucella abortus using MS-driven comparative proteomics. J Proteome Res 2012, 11:2374-2385.
11. Vranakis I., De Bock P.J., Papadioti A., Tselentis Y., Gevaert K., Tsiotis G., et al. Identification of potentially involved proteins in levofloxacin resistance mechanisms in Coxiella burnetii. J Proteome Res 2011, 10:756-762.
12. Vranakis I., De Bock P.J., Papadioti A., Tselentis Y., Gevaert K., Tsiotis G., et al. Quantitative proteome profiling of C. burnetii under tetracycline stress conditions. PLoS One 2012, 7:e33599.
13. Wright G. The antibiotic resistome: the nexus of chemical and genetic diversity. Nat Rev Microbiol 2007, 5:175-186.
14. Wright G.D. Antibiotics: a new hope. Chem Biol 2012, 19:3-10.
15. Martinez J., Baquero F., Andersson D. Predicting antibiotic resistance. Nat Rev Microbiol 2007, 5:958-965.
16. Fournier P.E., Drancourt M., Raoult D. Bacterial genome sequencing and its use in infectious diseases. Lancet Infect Dis 2007, 7:711-723.
17. Tonella L., Hoogland C., Binz P.A., Appel R.D., Hochstrasser D.F., Sanchez J.C. New perspectives in the Escherichia coli proteome investigation. Proteomics 2001, 1:409-423.
18. Malmstrom L., Malmstrom J., Aebersold R. Quantitative proteomics of microbes: principles and applications to virulence. Proteomics 2011, 11:2947-2956.
19. Sa-Correia I., Teixeira M.C. 2D electrophoresis-based expression proteomics: a microbiologist's perspective. Expert Rev Proteomics 2010, 7:943-953.
20. Unlu M., Morgan M.E., Minden J.S. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997, 18:2071-2077.
21. Washburn M.P., Wolters D., Yates J.R. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001, 19:242-247.
22. Oda Y., Nagasu T., Chait B.T. Enrichment analysis of phosphorylated proteins as a tool for probing the phosphoproteome. Nat Biotechnol 2001, 19:379-382.
23. Gevaert K., Van Damme J., Goethals M., Thomas G.R., Hoorelbeke B., Demol H., et al. Chromatographic isolation of methionine-containing peptides for gel-free proteome analysis: identification of more than 800 Escherichia coli proteins. Mol Cell Proteomics 2002, 1:896-903.
24. Gevaert K., Van Damme P., Ghesquière B., Impens F., Martens L., Helsens K., et al. A la carte proteomics with an emphasis on gel-free techniques. Proteomics 2007, 7:2698-2718.
25. Gygi S.P., Rist B., Gerber S.A., Turecek F., Gelb M.H., Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999, 17:994-999.
26. Ong S.E., Blagoev B., Kratchmarova I., Kristensen D.B., Steen H., Pandey A., et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002, 1:376-386.
27. Thompson A., Schäfer J., Kuhn K., Kienle S., Schwarz J., Schmidt G., et al. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal Chem 2003, 75:1895-1904.
28. Ross P.L., Huang Y.N., Marchese J.N., Williamson B., Parker K., Hattan S., et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004, 3:1154-1169.
29. Krijgsveld J., Ketting R.F., Mahmoudi T., Johansen J., Artal-Sanz M., Verrijzer C.P., et al. Metabolic labeling of C. elegans and D. melanogaster for quantitative proteomics. Nat Biotechnol 2003, 21:927-931.
30. Vranakis I., De Bock P.J., Papadioti A., Samoilis G., Tselentis Y., Gevaert K., et al. Unraveling persistent host cell infection with Coxiella burnetii by quantitative proteomics. J Proteome Res 2011, 10:4241-4251.
31. Papadioti A., De Bock P.-J., Vranakis I., Tselentis Y., Gevaert K., Psaroulaki A., et al. Study of the whole cell lysate of two coxiella burnetii strains using N-terminomics. J Proteome Res 2012, 11:3150-3159.
32. Dickerhof N., Kleffmann T., Jack R., McCormick S. Bacitracin inhibits the reductive activity of protein disulfide isomerase by disulfide bond formation with free cysteines in the substrate-binding domain. FEBS J 2011, 278:2034-2043.
33. Schonbrunn E., Sack S., Eschenburg S., Perrakis A., Krekel F., Amrhein N., et al. Crystal structure of UDP-N-acetylglucosamine enolpyruvyltransferase, the target of the antibiotic fosfomycin. Structure 1996, 4:1065-1075.
34. Wargel R.J., Shadur C.A., Neuhaus F.C. Mechanism of d-cycloserine action: transport systems for d-alanine, d-cycloserine, l-alanine, and glycine. J Bacteriol 1970, 103:778-788.
35. Bush K. Proliferation and significance of clinically relevant beta-lactamases. Ann N Y Acad Sci 2013, 1277:84-90.
36. Poole K. Efflux pumps as antimicrobial resistance mechanisms. Ann Med 2007, 39:162-176.
37. Zapun A., Contreras-Martel C., Vernet T. Penicillin-binding proteins and beta-lactam resistance. FEMS Microbiol Rev 2008, 32:361-385.
38. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1-12.
39. Llaca-Diaz J.M., Mendoza-Olazaran S., Camacho-Ortiz A., Flores S., Garza-Gonzalez E. One-year surveillance of ESKAPE pathogens in an intensive care unit of Monterrey, Mexico. Chemotherapy 2012, 58:475-481.
40. Rice L.B. Progress and challenges in implementing the research on ESKAPE pathogens. Infect Control Hosp Epidemiol 2010, 31(Suppl. 1):S7-S10.
41. Master R.N., Deane J., Opiela C., Sahm D.F. Recent trends in resistance to cell envelope-active antibacterial agents among key bacterial pathogens. Ann N Y Acad Sci 2013, 1277:1-7.
42. Soualhine H., Brochu V., Menard F., Papadopoulou B., Weiss K., Bergeron M.G., et al. A proteomic analysis of penicillin resistance in Streptococcus pneumoniae reveals a novel role for PstS, a subunit of the phosphate ABC transporter. Mol Microbiol 2005, 58:1430-1440.
43. Chaussee M.A., McDowell E.J., Rieck L.D., Callegari E.A., Chaussee M.S. Proteomic analysis of a penicillin-tolerant rgg mutant strain of Streptococcus pyogenes. J Antimicrob Chemother 2006, 58:752-759.
44. Hu W.S., Lin Y.H., Shih C.C. A proteomic approach to study Salmonella enterica serovar Typhimurium putative transporter YjeH associated with ceftriaxone resistance. Biochem Biophys Res Commun 2007, 361:694-699.
45. dos Santos K.V., Diniz C.G., Veloso Lde C., de Andrade H.M., Giusta Mda S., Pires Sda F., et al. Proteomic analysis of Escherichia coli with experimentally induced resistance to piperacillin/tazobactam. Res Microbiol 2010, 161:268-275.
46. Sulavik M.C., Houseweart C., Cramer C., Jiwani N., Murgolo N., Greene J., et al. Antibiotic susceptibility profiles of Escherichia coli strains lacking multidrug efflux pump genes. Antimicrob Agents Chemother 2001, 45:1126-1136.
47. Monteiro R., Vitorino R., Domingues P., Radhouani H., Carvalho C., Poeta P., et al. Proteome of a methicillin-resistant Staphylococcus aureus clinical strain of sequence type ST398. J Proteomics 2012, 75:2892-2915.
48. Liu W., Zou D., Wang X., Li X., Zhu L., Yin Z., et al. Proteomic analysis of clinical isolate of Stenotrophomonas maltophilia with blaNDM-1, blaL1 and blaL2 beta-lactamase genes under imipenem treatment. J Proteome Res 2012, 11:4024-4033.
49. Van Oudenhove L., De Vriendt K., Van Beeumen J., Mercuri P.S., Devreese B. Differential proteomic analysis of the response of Stenotrophomonas maltophilia to imipenem. Appl Microbiol Biotechnol 2012, 95:717-733.
50. Tiwari V., Vashistt J., Kapil A., Moganty R.R. Comparative proteomics of inner membrane fraction from carbapenem-resistant Acinetobacter baumannii with a reference strain. PLoS One 2012, 7:e39451.
51. Cetinkaya Y., Falk P., Mayhall C.G. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000, 13:686-707.
52. Pieper R., Gatlin-Bunai C.L., Mongodin E.F., Parmar P.P., Huang S.T., Clark D.J., et al. Comparative proteomic analysis of Staphylococcus aureus strains with differences in resistance to the cell wall-targeting antibiotic vancomycin. Proteomics 2006, 6:4246-4258.
53. Drummelsmith J., Winstall E., Bergeron M.G., Poirier G.G., Ouellette M. Comparative proteomics analyses reveal a potential biomarker for the detection of vancomycin-intermediate Staphylococcus aureus strains. J Proteome Res 2007, 6:4690-4702.
54. Wang X., He X., Jiang Z., Wang J., Chen X., Liu D., et al. Proteomic analysis of the Enterococcus faecalis V583 strain and clinical isolate V309 under vancomycin treatment. J Proteome Res 2010, 9:1772-1785.
55. Chen H., Liu Y., Zhao C., Xiao D., Zhang J., Zhang F., et al. Comparative proteomics-based identification of genes associated with glycopeptide resistance in clinically derived heterogeneous vancomycin-intermediate Staphylococcus aureus strains. PLoS One 2013, 8:e66880.
56. Straus S.K., Hancock R.E. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim Biophys Acta 2006, 1758:1215-1223.
57. Dabul A.N., Camargo I.L. Molecular characterization of methicillin-resistant Staphylococcus aureus resistant to tigecycline and daptomycin isolated in a hospital in Brazil. Epidemiol Infect 2013, 1-5.
58. Yu R., Dale S.E., Yamamura D., Stankus V., Lee C. Daptomycin-nonsusceptible, vancomycin-intermediate, methicillin-resistant Staphylococcus aureus endocarditis. Can J Infect Dis Med Microbiol 2012, 23:e48-e50.
59. Baltz R.H. Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr Opin Chem Biol 2009, 13:144-151.
60. Fischer A., Yang S.J., Bayer A.S., Vaezzadeh A.R., Herzig S., Stenz L., et al. Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach. J Antimicrob Chemother 2011, 66:1696-1711.
61. Seo M.D., Won H.S., Kim J.H., Mishig-Ochir T., Lee B.J. Antimicrobial peptides for therapeutic applications: a review. Molecules 2012, 17:12276-12286.
62. Chiu Y., Kuo T.Y., Lin C.C., Chen W.J. Proteomic analysis reveals responsive proteins of Vibrio parahaemolyticus on exposure to cationic antimicrobial peptides. J Appl Microbiol 2011, 110:80-89.
63. Fehri L.F., Sirand-Pugnet P., Gourgues G., Jan G., Wroblewski H., Blanchard A. Resistance to antimicrobial peptides and stress response in Mycoplasma pulmonis. Antimicrob Agents Chemother 2005, 49:4154-4165.
64. Lin X.M., Li H., Wang C., Peng X.X. Proteomic analysis of nalidixic acid resistance in Escherichia coli: identification and functional characterization of OM proteins. J Proteome Res 2008, 7:2399-2405.
65. Li H., Lin X.M., Wang S.Y., Peng X.X. Identification and antibody-therapeutic targeting of chloramphenicol-resistant outer membrane proteins in Escherichia coli. J Proteome Res 2007, 6:3628-3636.
66. Shen C.J., Kuo T.Y., Lin C.C., Chow L.P., Chen W.J. Proteomic identification of membrane proteins regulating antimicrobial peptide resistance in Vibrio parahaemolyticus. J Appl Microbiol 2010, 108:1398-1407.
67. Maria-Neto S., Candido Ede S., Rodrigues D.R., de Sousa D.A., da Silva E.M., de Moraes L.M., et al. Deciphering the magainin resistance process of Escherichia coli strains in light of the cytosolic proteome. Antimicrob Agents Chemother 2012, 56:1714-1724.
68. Fidai S., Farmer S.W., Hancock R.E. Interaction of cationic peptides with bacterial membranes. Methods Mol Biol 1997, 78:187-204.
69. Fernandez-Reyes M., Rodriguez-Falcon M., Chiva C., Pachon J., Andreu D., Rivas L. The cost of resistance to colistin in Acinetobacter baumannii: a proteomic perspective. Proteomics 2009, 9:1632-1645.
70. Chopra I., Hawkey P.M., Hinton M. Tetracyclines, molecular and clinical aspects. J Antimicrob Chemother 1992, 29:245-277.
71. Brodersen D.E., Clemons W.M., Carter A.P., Morgan-Warren R.J., Wimberly B.T., Ramakrishnan V. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell 2000, 103:1143-1154.
72. Thaker M., Spanogiannopoulos P., Wright G.D. The tetracycline resistome. Cell Mol Life Sci 2010, 67:419-431.
73. Zhang D.F., Jiang B., Xiang Z.M., Wang S.Y. Functional characterisation of altered outer membrane proteins for tetracycline resistance in Escherichia coli. Int J Antimicrob Agents 2008, 32:315-319.
74. Chao C.C., Garland D.L., Dasch G.A., Ching W.M. Comparative proteomic analysis of antibiotic-sensitive and insensitive isolates of Orientia tsutsugamushi. Ann N Y Acad Sci 2009, 1166:27-37.
75. Yun S.-H., Choi C.-W., Park S.-H., Lee J., Leem S.-H., Choi J.-S., et al. Proteomic analysis of outer membrane proteins from Acinetobacter baumannii DU202 in tetracycline stress condition. J Microbiol 2008, 46:720-727.
76. Peng X., Xu C., Ren H., Lin X., Wu L., Wang S. Proteomic analysis of the sarcosine-insoluble outer membrane fraction of Pseudomonas aeruginosa responding to ampicillin, kanamycin, and tetracycline resistance. J Proteome Res 2005, 4:2257-2265.
77. Jones D., Metzger H.J., Schatz A., Waksman S.A. Control of Gram-negative bacteria in experimental animals by streptomycin. Science 1944, 100:103-105.
78. Fritsche T.R., Castanheira M., Miller G.H., Jones R.N., Armstrong E.S. Detection of methyltransferases conferring high-level resistance to aminoglycosides in enterobacteriaceae from Europe, North America, and Latin America. Antimicrob Agents Chemother 2008, 52:1843-1845.
79. Mingeot-Leclercq M.P., Glupczynski Y., Tulkens P.M. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 1999, 43:727-737.
80. Springer B., Kidan Y.G., Prammananan T., Ellrott K., Bottger E.C., Sander P. Mechanisms of streptomycin resistance: selection of mutations in the 16S rRNA gene conferring resistance. Antimicrob Agents Chemother 2001, 45:2877-2884.
81. Krahmer M., Walters J., Fox K., Fox A., Creek K.E., Pirisi L., et al. MS for identification of single nucleotide polymorphisms and MS/MS for discrimination of isomeric PCR products. Anal Chem 2000, 72:4033-4040.
82. Sharma P., Kumar B., Gupta Y., Singhal N., Katoch V.M., Venkatesan K., et al. Proteomic analysis of streptomycin resistant and sensitive clinical isolates of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 2010, 8:59.
83. Cash P., Argo E., Ford L., Lawrie L., McKenzie H. A proteomic analysis of erythromycin resistance in Streptococcus pneumoniae. Electrophoresis 1999, 20:2259-2268.
84. Ehrlich J., Gottlieb D., Burkholder P., Anderson L., Pridham T. Streptomyces venezuelae, n. sp., the source of chloromycetin. J Bacteriol 1948, 56:467-477.
85. Biot F.V., Valade E., Garnotel E., Chevalier J., Villard C., Thibault F.M., et al. Involvement of the efflux pumps in chloramphenicol selected strains of Burkholderia thailandensis: proteomic and mechanistic evidence. PLoS One 2011, 6:e16892.
86. Drlica K., Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997, 61:377-392.
87. Hooper D.C. Mechanisms of quinolone resistance. Quinolone antimicrobial agents 2003, American Society for Microbiology Press, Washington, DC. 3rd ed. E. HR (Ed.).
88. Beck M., Malmstrom J.A., Lange V., Schmidt A., Deutsch E.W., Aebersold R. Visual proteomics of the human pathogen Leptospira interrogans. Nat Methods 2009, 6:817-823.
89. Poutanen M., Varhimo E., Kalkkinen N., Sukura A., Varmanen P., Savijoki K. Two-dimensional difference gel electrophoresis analysis of Streptococcus uberis in response to mutagenesis-inducing ciprofloxacin challenge. J Proteome Res 2009, 8:246-255.
90. Coldham N.G., Randall L.P., Piddock L.J., Woodward M.J. Effect of fluoroquinolone exposure on the proteome of Salmonella enterica serovar Typhimurium. J Antimicrob Chemother 2006, 58:1145-1153.
91. Sorlozano A., Gutierrez J., Jimenez A., de Dios Luna J., Martinez J.L. Contribution of a new mutation in parE to quinolone resistance in extended-spectrum-beta-lactamase-producing Escherichia coli isolates. J Clin Microbiol 2007, 45:2740-2742.
92. Vranakis I., Sandalakis V., Chochlakis D., Tselentis Y., Psaroulaki A. DNA gyrase and topoisomerase IV mutations in an in vitro fluoroquinolone-resistant Coxiella burnetii strain. Microb Drug Resist 2010, 16:111-117.
93. Li P., Liu X., Li H., Peng X.X. Downregulation of Na(+)-NQR complex is essential for Vibrio alginolyticus in resistance to balofloxacin. J Proteomics 2012, 75:2638-2648.
94. Neri A., Mignogna G., Fazio C., Giorgi A., Schinina M.E., Stefanelli P. Neisseria meningitidis rifampicin resistant strains: analysis of protein differentially expressed. BMC Microbiol 2010, 10:246.
95. Dwyer D.J., Kohanski M.A., Collins J.J. Role of reactive oxygen species in antibiotic action and resistance. Curr Opin Microbiol 2009, 12:482-489.